{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:21:29Z","timestamp":1790115689977,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007489","name":"Bausch and Lomb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007489","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40123-025-01302-z","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T16:07:41Z","timestamp":1769443661000},"page":"817-829","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Perfluorohexyloctane Ophthalmic Solution in Patients with Dry Eye Disease Undergoing Cataract Surgery: A Prospective Multicenter Study"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct06346340","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"John A.","family":"Hovanesian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel R.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg J.","family":"Berdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Karpuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Schweitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason L.","family":"Vittitow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Berdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Bacharach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"issue":"8","key":"1302_CR1","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/s41433-025-03745-x","volume":"39","author":"D O'Brart","year":"2025","unstructured":"O\u2019Brart D. The future of cataract surgery. Eye Lond. 2025;39(8):1451\u20136.","journal-title":"Eye Lond"},{"issue":"11","key":"1302_CR2","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.ophtha.2019.03.033","volume":"126","author":"JT Cox","year":"2019","unstructured":"Cox JT, Subburaman GB, Munoz B, Friedman DS, Ravindran RD. Visual acuity outcomes after cataract surgery: high-volume versus low-volume surgeons. Ophthalmology. 2019;126(11):1480\u20139.","journal-title":"Ophthalmology"},{"issue":"2","key":"1302_CR3","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/eye.2013.248","volume":"28","author":"R Sheard","year":"2014","unstructured":"Sheard R. Optimising biometry for best outcomes in cataract surgery. Eye Lond. 2014;28(2):118\u201325.","journal-title":"Eye Lond"},{"issue":"1","key":"1302_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/ICU.0b013e32834cd63e","volume":"23","author":"A Sahin","year":"2012","unstructured":"Sahin A, Hamrah P. Clinically relevant biometry. Curr Opin Ophthalmol. 2012;23(1):47\u201353.","journal-title":"Curr Opin Ophthalmol"},{"key":"1302_CR5","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.2147\/OPTH.S406530","volume":"17","author":"K Biela","year":"2023","unstructured":"Biela K, Winiarczyk M, Borowicz D, Mackiewicz J. Dry eye disease as a cause of refractive errors after cataract surgery - a systematic review. Clin Ophthalmol. 2023;17:1629\u201338.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"1302_CR6","doi-asserted-by":"publisher","first-page":"26762","DOI":"10.1038\/s41598-024-77572-7","volume":"14","author":"S Ahn","year":"2024","unstructured":"Ahn S, Eom Y, Song JS, Kim DH. Short-term variability in ocular biometry and the impact of preoperative dry eye. Sci Rep. 2024;14(1):26762.","journal-title":"Sci Rep"},{"issue":"3","key":"1302_CR7","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276\u201383.","journal-title":"Ocul Surf"},{"issue":"5","key":"1302_CR8","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1177\/1120672120929958","volume":"30","author":"K Naderi","year":"2020","unstructured":"Naderi K, Gormley J, O\u2019Brart D. Cataract surgery and dry eye disease: a review. Eur J Ophthalmol. 2020;30(5):840\u201355.","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"1302_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/08820538.2022.2112699","volume":"38","author":"AS Nibandhe","year":"2023","unstructured":"Nibandhe AS, Donthineni PR. Understanding and optimizing ocular biometry for cataract surgery in dry rye disease: a review. Semin Ophthalmol. 2023;38(1):24\u201330.","journal-title":"Semin Ophthalmol"},{"issue":"6","key":"1302_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering11060597","volume":"11","author":"A Kawahara","year":"2024","unstructured":"Kawahara A. Management of dry eye disease for intraocular lens power calculation in cataract surgery: a systematic review. Bioengineering. 2024;11(6):597.","journal-title":"Bioengineering"},{"issue":"3","key":"1302_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-067007","volume":"13","author":"KG Boboridis","year":"2023","unstructured":"Boboridis KG, Messmer EM, Ben\u00edtez-Del-Castillo J, et al. Patient-reported burden and overall impact of dry eye disease across eight European countries: a cross-sectional web-based survey. BMJ Open. 2023;13(3):e067007.","journal-title":"BMJ Open"},{"key":"1302_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ajo.2017.06.033","volume":"182","author":"KF Farrand","year":"2017","unstructured":"Farrand KF, Fridman M, Stillman I\u00d6, Schaumberg DA. Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. Am J Ophthalmol. 2017;182:90\u20138.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"1302_CR13","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.4103\/IJO.IJO_2807_22","volume":"71","author":"PR Donthineni","year":"2023","unstructured":"Donthineni PR, Deshmukh R, Ramamurthy C, Sangwan VS, Mehta JS, Basu S. Management of cataract in dry eye disease: preferred practice pattern guidelines. Indian J Ophthalmol. 2023;71(4):1364\u201372.","journal-title":"Indian J Ophthalmol"},{"issue":"5","key":"1302_CR14","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/j.jcrs.0000000000000844","volume":"48","author":"K Donaldson","year":"2022","unstructured":"Donaldson K, Parkhurst G, Saenz B, Whitley W, Williamson B, Hovanesian J. Call to action: treating dry eye disease and setting the foundation for successful surgery. J Cataract Refract Surg. 2022;48(5):623\u20139.","journal-title":"J Cataract Refract Surg"},{"key":"1302_CR15","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2147\/OPTH.S120159","volume":"11","author":"WB Trattler","year":"2017","unstructured":"Trattler WB, Majmudar PA, Donnenfeld ED, McDonald MB, Stonecipher KG, Goldberg DF. The prospective health assessment of cataract patients\u2019 ocular surface (PHACO) study: the effect of dry eye. Clin Ophthalmol. 2017;11:1423\u201330.","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"1302_CR16","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1177\/11206721221141481","volume":"33","author":"EM Messmer","year":"2023","unstructured":"Messmer EM, Ahmad S, Benitez Del Castillo JM, et al. Management of inflammation in dry eye disease: recommendations from a European panel of experts. Eur J Ophthalmol. 2023;33(3):1294\u2013307.","journal-title":"Eur J Ophthalmol"},{"issue":"4","key":"1302_CR17","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1016\/j.ophtha.2023.12.041","volume":"131","author":"G Amescua","year":"2024","unstructured":"Amescua G, Ahmad S, Cheung AY, et al. Dry eye syndrome Preferred Practice Pattern\u00ae. Ophthalmology. 2024;131(4):P1\u201349.","journal-title":"Ophthalmology"},{"key":"1302_CR18","unstructured":"MIEBO (perfluorohexyloctane ophthalmic solution), for topical ophthalmic use. Package insert. Bausch & Lomb Americas Inc; 2023."},{"key":"1302_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2023.100704","volume":"98","author":"J Vittitow","year":"2023","unstructured":"Vittitow J, Kissling R, DeCory H, Borchman D. In vitro inhibition of evaporation with perfluorohexyloctane, an eye drop for dry eye disease. Curr Ther Res Clin Exp. 2023;98:100704.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"3","key":"1302_CR20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1089\/jop.2019.0092","volume":"36","author":"D Schmidl","year":"2020","unstructured":"Schmidl D, Bata AM, Szegedi S, et al. Influence of perfluorohexyloctane eye drops on tear film thickness in patients with mild to moderate dry eye disease: a randomized controlled clinical trial. J Ocul Pharmacol Ther. 2020;36(3):154\u201361.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"7","key":"1302_CR21","first-page":"370","volume":"41","author":"S Kr\u00f6sser","year":"2025","unstructured":"Kr\u00f6sser S, Grillenberger R, Eickhoff K, Korward J, Cavet ME, Mah FS. Ocular pharmacokinetics and biodistribution of perfluorohexyloctane after topical administration to rabbits. J Ocul Pharmacol Ther. 2025;41(7):370\u20137.","journal-title":"J Ocul Pharmacol Ther."},{"issue":"5","key":"1302_CR22","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ophtha.2022.12.021","volume":"130","author":"J Tauber","year":"2023","unstructured":"Tauber J, Berdy GJ, Wirta DL, Kr\u00f6sser S, Vittitow JL, on behalf of the GOBI Study Group. NOV03 for dry eye disease associated with meibomian gland dysfunction: results of the randomized phase 3 GOBI study. Ophthalmology. 2023;130(5):516\u201324.","journal-title":"Ophthalmology"},{"key":"1302_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ajo.2023.03.008","volume":"252","author":"JD Sheppard","year":"2023","unstructured":"Sheppard JD, Kurata F, Epitropoulos AT, Kr\u00f6sser S, Vittitow JL, MOJAVE Study Group. NOV03 for signs and symptoms of dry eye disease associated with meibomian gland dysfunction: the randomized phase 3 MOJAVE study. Am J Ophthalmol. 2023;252:265\u201374.","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"1302_CR24","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1097\/ICO.0000000000003418","volume":"43","author":"EE Protzko","year":"2024","unstructured":"Protzko EE, Segal BA, Korenfeld MS, Kr\u00f6sser S, Vittitow JL. Long-term safety and efficacy of perfluorohexyloctane ophthalmic solution for the treatment of patients with dry eye disease: the KALAHARI study. Cornea. 2024;43(9):1100\u20137.","journal-title":"Cornea"},{"issue":"8","key":"1302_CR25","volume":"66","author":"K Karpuk","year":"2025","unstructured":"Karpuk K, Ferguson T. The impact of a single drop of perfluorohexyloctane ophthalmic solution (MIEBO\u2122) has on biometry measurements and intraocular lens calculations. Invest Ophthalmol Vis Sci. 2025;66(8):5627.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"1302_CR26","first-page":"221","volume":"21","author":"MA Lemp","year":"1995","unstructured":"Lemp MA. Report of the National Eye Institute\/industry workshop on clinical trials in dry eyes. CLAO J. 1995;21(4):221\u201332.","journal-title":"CLAO J"},{"issue":"5","key":"1302_CR27","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/archopht.118.5.615","volume":"118","author":"RM Schiffman","year":"2000","unstructured":"Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the ocular surface disease index. Arch Ophthalmol. 2000;118(5):615\u201321.","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"1302_CR28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1001\/archophthalmol.2009.356","volume":"128","author":"KM Miller","year":"2010","unstructured":"Miller KM, Walt JG, Mink DR, et al. Minimal clinically important difference for the ocular surface disease index. Arch Ophthalmol. 2010;128(1):94\u2013101.","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"1302_CR29","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12886-023-03067-0","volume":"23","author":"S Zhou","year":"2023","unstructured":"Zhou S, Chen X, Ortega-Usobiaga J, et al. Characteristics and influencing factors of corneal higher-order aberrations in patients with cataract. BMC Ophthalmol. 2023;23(1):313.","journal-title":"BMC Ophthalmol"},{"issue":"6","key":"1302_CR30","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1097\/j.jcrs.0000000000001423","volume":"50","author":"EK Akpek","year":"2024","unstructured":"Akpek EK, Sheppard JD, Hamm A, Angstmann-Mehr S, Kr\u00f6sser S. Efficacy of a new water-free topical cyclosporine 0.1% solution for optimizing the ocular surface in patients with dry eye and cataract. J Cataract Refract Surg. 2024;50(6):644\u201350.","journal-title":"J Cataract Refract Surg"},{"issue":"3","key":"1302_CR31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4274\/tjo.galenos.2019.45538","volume":"50","author":"P Garg","year":"2020","unstructured":"Garg P, Gupta A, Tandon N, Raj P. Dry eye disease after cataract surgery: study of its determinants and risk factors. Turk J Ophthalmol. 2020;50(3):133\u201342.","journal-title":"Turk J Ophthalmol"},{"key":"1302_CR32","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.2147\/OPTH.S114890","volume":"10","author":"A Gibbons","year":"2016","unstructured":"Gibbons A, Ali TK, Waren DP, Donaldson KE. Causes and correction of dissatisfaction after implantation of presbyopia-correcting intraocular lenses. Clin Ophthalmol. 2016;10:1965\u201370.","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"1302_CR33","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1007\/s12325-020-01288-z","volume":"37","author":"P Fogagnolo","year":"2020","unstructured":"Fogagnolo P, Favuzza E, Marchina D, et al. New therapeutic strategy and innovative lubricating ophthalmic solution in minimizing dry eye disease associated with cataract surgery: a randomized, prospective study. Adv Ther. 2020;37(4):1664\u201374.","journal-title":"Adv Ther"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01302-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01302-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01302-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:26:27Z","timestamp":1770902787000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01302-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1302"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01302-z","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"John A. Hovanesian reports serving as a consultant to Bausch\u2009+\u2009Lomb. Eva Liang reports serving as a consultant to Bausch\u2009+\u2009Lomb. Neel R. Desai reports serving as a speaker\/consultant for Alcon, Bausch\u2009+\u2009Lomb, Biotissue, Domp\u00e9, E-Swin, Glaukos, Johnson and Johnson, LayerBio, LensAR, RxSight, Sight Sciences, and Spyglass; and being a shareholder of Alcon, Biotissue, Glaukos, LayerBio, and Sight Sciences. Gregg J. Berdy reports serving as a consultant or as a member of advisory boards for Alcon Laboratories, Inc, Allergan, Avellino Labs, Bausch\u2009+\u2009Lomb, Domp\u00e9, Novartis (Alcon Pharmaceuticals), Sun Pharma, and TearScience; and receiving honoraria for lecturing as part of the speaker\u2019s bureau for Alcon Laboratories, Allergan, Avellino Labs, Bausch\u2009+\u2009Lomb, Domp\u00e9, Novartis (Alcon Pharmaceuticals), and Sun Pharma. Kayla Karpuk reports serving as a consultant for Tarsus. Justin Schweitzer reports serving as a consultant or speaker for Alcon, Allergan\/AbbVie, Bausch\u2009+\u2009Lomb, Bruder, Domp\u00e9, Glaukos, Iveric Bio, LKC Technologies, MediPrint Ophthalmics, Ocuphire Pharma, Inc, Reichert Technologies, ScienceBased Health, Sight Sciences, Sun Pharmaceutical Industries Ltd, Tarsus Pharmaceuticals, Th\u00e9a, Topcon Healthcare, Trukera Medical, Visus Therapeutics, and Zeiss; and serving as Chief Medical Editor for Modern Optometry. Adam Alexander and Jason L. Vittitow are employees of Bausch\u2009+\u2009Lomb. John Berdahl reports serving as a consultant\/advisor for AbbVie, Aerpio, ALJ Health, Alcon, Aldeyra, Allergan, Aquea Health, Aurea Medical, Aurion Biotech, Avelinno, Balance Ophthalmics, Bausch\u2009+\u2009Lomb, Belkin, Centricity Vision, CorneaGen, Dakota Lions Eye Bank, Elios Vision, Equinox, Expert Opinion, Glaukos, Gore, Greenman, Horizon Surgical, Iacta Pharmaceuticals, Ilevro, Imprimis, Interfeen, iRenix, Iveric Bio, Johnson and Johnson, Kala, Kedalion, MELT Pharmaceuticals, MicrOptx, New World Medical, Ocular Surgical Data, Ocular Therapeutix, Omega Ophthalmic, Orasis, Oyster Point, RxSight, Santen, Sight Sciences, Surface, Tarsus, TavoBio, Tear Clear, Tissue Gen, Vance Thompson Vision, Versea Biologics, Vertex Ventures, ViaLase, Visionary Ventures, Visus, Vittamed, and Zeiss; serving as a lecturer for AbbVie, Alcon, Glaukos; having equity ownership or stock options in Aurion Biotech, Balance Ophthalmics, CorneaGen, Equinox, Expert Opinion, Glaukos, Interfeen, LayerBio, Ocular Surgical Data, Omega Ophthalmic, Surface, True North CRO, Vance Thompson Vision, Verana Health, and Zeiss; and receiving royalties from Imprimis. Jason Bacharach reports being a consultant and conducting research for Bausch\u2009+\u2009Lomb.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the Helsinki Declaration of 1964, its later amendments, and the principles of Good Clinical Practice. The study protocol was approved by a central institutional review board (Advarra IRB; Columbia, MD, USA).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All patients provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}